Stay updated on PDR001 with Chemo and Immunology Agents in NSCLC Clinical Trial
Sign up to get notified when there's something new on the PDR001 with Chemo and Immunology Agents in NSCLC Clinical Trial page.

Latest updates to the PDR001 with Chemo and Immunology Agents in NSCLC Clinical Trial page
- Check2 days agoChange DetectedA new publication citation is added to the Publications section, reporting Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in PD-L1-unselected, metastatic NSCLC. The publication record is updated to Revision: v3.5.4, replacing the prior v3.5.3 entry.SummaryDifference0.1%

- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe page’s displayed revision version was incremented from **v3.5.2** to **v3.5.3**, reflecting a site/version update without altering the study details shown.SummaryDifference0.0%

- Check30 days agoChange DetectedThe Spartalizumab publication citation was updated to Revision: v3.5.2 with an erratum added, replacing the previous Revision: v3.5.0.SummaryDifference0.1%

- Check52 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0 on the page.SummaryDifference0.0%

- Check66 days agoChange DetectedRevision history updated: added Revision: v3.4.3 and removed Revision: v3.4.2.SummaryDifference0.0%

- Check94 days agoChange DetectedAdded site revision tag v3.4.2 and removed the prior funding/status notice (v3.4.1); these are maintenance updates to the site interface and do not affect trial content or user actions. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

Stay in the know with updates to PDR001 with Chemo and Immunology Agents in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PDR001 with Chemo and Immunology Agents in NSCLC Clinical Trial page.